Hans Gelderblom
汉斯·赫尔德布洛姆
MD, PhD
Professor of Medical Oncology; Head, Sarcoma & Bone Tumors Program
👥Biography 个人简介
Hans Gelderblom, MD, PhD is Professor of Medical Oncology and Head of the Sarcoma and Bone Tumors Program at Leiden University Medical Center in the Netherlands. He is one of Europe's leading sarcoma clinicians and trial investigators, with extensive contributions to both soft tissue and bone sarcoma clinical research. His work spans first-in-human pharmacology studies, pivotal phase III trials, and translational investigations into chemotherapy resistance mechanisms in osteosarcoma and Ewing sarcoma. Dr. Gelderblom has been a senior investigator and national coordinator for multiple EORTC Soft Tissue and Bone Sarcoma Group trials, including landmark studies of trabectedin, pazopanib, and novel combination regimens. He is a recognized leader in the pharmacology of anticancer agents used in sarcoma and has authored over 300 peer-reviewed publications. He serves on the ESMO Clinical Practice Guidelines Committee for Sarcoma and the NCCN Bone Cancer Panel.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EORTC Soft Tissue and Bone Sarcoma Group Trial Leadership
Served as national PI and co-investigator for numerous EORTC sarcoma landmark trials including PALETTE (pazopanib), and multiple bone sarcoma studies, significantly contributing to the evidentiary base for current European sarcoma treatment standards.
Gemcitabine-Docetaxel in Soft Tissue Sarcoma
Led pivotal studies evaluating gemcitabine-docetaxel combination chemotherapy in leiomyosarcoma and other soft tissue sarcoma histotypes, contributing to the establishment of this regimen as a standard second-line option and refining its use through pharmacological and translational analyses.
Osteosarcoma Clinical Trial Development
Principal investigator for EURAMOS-1, the largest international randomized trial in osteosarcoma, evaluating addition of interferon-alpha and/or ifosfamide/etoposide to standard MAP chemotherapy based on histological response, providing crucial data on treatment intensification strategies.
Pharmacology and Toxicity of Anticancer Agents in Sarcoma
Conducted extensive clinical pharmacological studies of taxanes, trabectedin, and eribulin in sarcoma, characterizing pharmacokinetic-pharmacodynamic relationships and identifying patient factors influencing drug exposure and toxicity to improve dosing strategies.
Representative Works 代表性著作
Pazopanib for metastatic soft-tissue sarcoma (PALETTE)
The Lancet (2012)
Phase III PALETTE trial demonstrating pazopanib improved progression-free survival versus placebo in non-adipocytic advanced soft tissue sarcoma, establishing pazopanib as the first approved targeted agent in this setting.
EURAMOS-1: an international randomized study for osteosarcoma
Annals of Oncology (2015)
Landmark phase III trial in osteosarcoma evaluating treatment intensification based on histological response to pre-operative chemotherapy, providing definitive evidence on the role of interferon-alpha maintenance and intensification strategies.
Gemcitabine and Docetaxel Versus Doxorubicin for First-Line Treatment of Stage IV or Recurrent Uterine Leiomyosarcoma
Journal of Clinical Oncology (2015)
Randomized trial comparing gemcitabine-docetaxel versus doxorubicin in uterine leiomyosarcoma, informing front-line chemotherapy selection in this major sarcoma subtype.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 汉斯·赫尔德布洛姆 的研究动态
Follow Hans Gelderblom's research updates
留下邮箱，当我们发布与 Hans Gelderblom（Leiden University Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment